Seven Abstracts to be Presented on Evofem Biosciences Vaginal pH Modulator prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention
News provided by
Share this article
Share this article
SAN DIEGO, March 16, 2021 /PRNewswire/ Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected
American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection. We believe publication of this important manuscript in such a prestigious peer-reviewed journal further validates these impressive AMPREVENCE trial outcomes and brings us one step closer to being able to provide a woman-controlled, discreet option for prevention of chlamydia and